Maxim Group Upgrades Kintara Therapeutics to Buy, Announces $14 Price Target
Portfolio Pulse from richadhand@benzinga.com
Maxim Group analyst Jason McCarthy has upgraded Kintara Therapeutics (NASDAQ:KTRA) from Hold to Buy and announced a $14 price target.
July 14, 2023 | 1:22 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Kintara Therapeutics has been upgraded from Hold to Buy by Maxim Group, with a new price target of $14.
The upgrade from Hold to Buy by Maxim Group indicates a positive outlook for Kintara Therapeutics. The new price target of $14 suggests potential upside for the stock. This could lead to increased investor interest and a potential rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100